Professor Anil Koul gave an 'Institute Seminar' on 'The Impact of Bedaquiline and the Promise of Next-Generation Medicines for drug resistant tuberculosis'. This seminar was jointly organized by the DBS and the DCS.

Prof. Koul is currently the Vice President and Head of Global Public Health Discovery & Partnerships at Johnson & Johnson. He is also an Adjunct Professor of Translational Discovery at the London School of Hygiene and Tropical Medicine (LSHTM), where his research group is engaged in translational medicine for tuberculosis.